Lumos Networks Carrier End User Team in Play at International Telecoms Week (“ITW”) in Chicago

WAYNESBORO, Va.--(BUSINESS WIRE)-- Lumos Networks Corp. (Nasdaq: LMOS), a leading fiber-based infrastructure provider in the mid-Atlantic region, will be attending ITW, which will be held May 8-11, 2016 at the Hyatt Regency Hotel & Swissotel in Chicago, Illinois.

ITW is a leading meeting point for the global wholesale telecom community. In 2015, over 6,000 delegates from 1,900 companies attended the event.

If you would like to schedule a meeting with the Lumos Networks Carrier End User/Wholesale Partnership sales team, please contact Roger Adamiak, Director of Strategic Sales, [email protected] and 412-963-7333.

About Lumos Networks

Lumos Networks is a leading fiber-based infrastructure provider in the Mid-Atlantic region serving Carrier, Enterprise and Data Center customers, offering end-to-end connectivity in 24 markets in Virginia, Pennsylvania, West Virginia, Maryland, Ohio and Kentucky. With a fiber network of 8,607 fiber route miles and more than 384,000 total fiber strand miles, Lumos Networks connects 1,099 unique Fiber to the Cell sites, 1,440 total FTTC connections, 36 data centers, including 7 company owned co-location facilities, 1,732 on-net buildings and over 2,800 total on-net locations. In 2015, Lumos Networks generated over $114 million in Data revenue and over $51 million in Adjusted EBITDA over our fiber network. Detailed information about Lumos Networks is available at www.lumosnetworks.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160427005449/en/

Lumos Networks Corp.
Financial Community Contact
Will Davis
Senior Vice President of Marketing and Investor Relations
Chief of Staff
917-519-6994
[email protected]
or
Media Contact
James Nester
Vice President of Marketing and Public Affairs
304-414-4667
[email protected]

Source: Lumos Networks Corp.

You May Also Be Interested In

• Form 8.5 (EPT/RI) - Mattioli Woods
• Sungrow Released Annual Report 2023: Operating Revenue Witnessed A Robust Growth of 79.5%
• FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease